An open label, randomized, two-treatment, two-sequence, four-period, single-dose, full replicate crossover bioequivalence study of GEN1501 (Insulin Glargine Injection) 100 U/mL of GeneSys Biologics Pvt. Ltd., Hyderabad, India and LANTUS® (Insulin Glargine Injection) 100 U/mL of Sanofi-Aventis, in healthy male, adult, human subjects under fasting conditions. - GEN1501
Latest Information Update: 30 Nov 2020
At a glance
- Drugs Insulin glargine (Primary)
- Indications Diabetes mellitus
- Focus Pharmacokinetics
- Sponsors GeneSys Biologics
- 30 Nov 2020 New trial record